Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study

Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study

Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treatment. The aim of this study is to assess the real-life outcomes of use of apremilast in patients with psoriasis in everyday clinical practice. A total of 159 adult patients (90 males) with plaque psor...

Full description

Bibliographic Details
Main Authors:	Giovanna Malara, Cristina Politi, Caterina Trifirò, Chiara Verduci, Graziella D'Arrigo, Alessandra Testa, Giovanni Tripepi
Format:	Article
Language:	English
Published:	Society for Publication of Acta Dermato-Venereologica 2021-09-01
Series:	Acta Dermato-Venereologica
Subjects:	psoriasis psoriatic arthritis apremilast obesity retention rate
Online Access:	https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3846

Similar Items

Apremilast: target synthetic drug for the treatment of psoriatic arthritis and psoriasis
by: Yu. L. Korsakova, et al.
Published: (2018-07-01)

Apremilast in psoriasis and beyond: Big hopes on a small molecule
by: T P Afra, et al.
Published: (2019-01-01)

Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01)

Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report
by: Roberta Gualtierotti, et al.
Published: (2019-03-01)

Dramatic response of cutaneous, nail, and joint symptoms of psoriasis to apremilast
by: Meghana Bathina, et al.
Published: (2019-01-01)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
by: Hagberg KW, et al.
Published: (2020-02-01)

Clinical potential of apremilast in the treatment of psoriatic arthritis
by: Cauli A, et al.
Published: (2014-06-01)

Apremilast: A dermatologic perspective
by: Aditya Kumar Bubna
Published: (2016-01-01)

Erythrodermic psoriasis treated with apremilast
by: John Arcilla, et al.
Published: (2016-09-01)

APREMILAST: AN UPDATE ON ITS EFFICACY AND SAFETY DURING LONG-TERM TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2018-11-01)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016-05-01)

The effect of Apremilast on signal transduction and IL-10 production in CD39high regulatory B cells in patients with psoriatic arthritis
by: Lazaros I. Sakkas, et al.
Published: (2018-01-01)

Real-world insight on apremilast therapy in patients with plaque psoriasis: Indian experience
by: Abhishek De, et al.
Published: (2020-01-01)

Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis
by: O. Yu. Olisova, et al.
Published: (2019-07-01)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
by: Thomas G. Salopek
Published: (2017-08-01)

Apremilast generic for the treatment of active psoriatic arthritis: A single-center real-life experience from India
by: Sanjiv Amin, et al.
Published: (2020-01-01)

Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic
by: Abhishek De, et al.
Published: (2019-01-01)

Apremilast in people living with HIV with psoriasis vulgaris: A case report
by: Bela J Shah, et al.
Published: (2019-01-01)

New opportunities in the treatment of psoriasis and psoriatic arthritis
by: A. A. Kubanov, et al.
Published: (2019-01-01)

The place of a phosphodiesterase 4 inhibitor in the treatment strategy for psoriatic arthritis
by: V. I. Mazurov, et al.
Published: (2018-04-01)

Use of phosphodiesterase 4 inhibitor in patients with psoriatic arthritis
by: V. I. Mazurov, et al.
Published: (2017-04-01)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
by: Rajagopalan M, et al.
Published: (2021-08-01)

The effect of apremilast therapy on skin cytokine levels in patients with psoriasis
by: Alexey A. Kubanov, et al.
Published: (2020-09-01)

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis
by: Arthur Kavanaugh, et al.
Published: (2019-05-01)

Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysisCapsule Summary
by: Thomas Graier, MD, et al.
Published: (2021-03-01)

Experience in the treatment of psoriasis patients using Apremilast, a selective signalling pathway inhibitor
by: N. V. Kungurov, et al.
Published: (2019-04-01)

Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series
by: Sascha Ständer, et al.
Published: (2020-10-01)

Beneficial Impact of Apremilast on Palmoplantar Keratodermas
by: Kimiko Nakajima, et al.
Published: (2021-04-01)

Crystal structure of an apremilast ethanol hemisolvate hemihydrate solvatomorph
by: Yun-Deng Wu, et al.
Published: (2017-06-01)

Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
by: Bela J Shah, et al.
Published: (2020-01-01)

Colocalization of psoriasis and vitiligo treated with apremilast and narrowband ultraviolet B combination in an adolescent girl
by: Trashita Hassanandani, et al.
Published: (2020-01-01)

THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2016-12-01)

Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom
by: Anthony Bewley, et al.
Published: (2018-01-01)

Real-world experience on the effectiveness and tolerability of apremilast in patients with plaque psoriasis in India
by: Shrichand Parasramani, et al.
Published: (2019-01-01)

Worsening of Lymphopenia during Apremilast Treatment
by: Antonios G.A. Kolios, et al.
Published: (2016-11-01)

The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
by: E. Yu. Loginova, et al.
Published: (2019-07-01)

Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients
by: Cohen-Sors R, et al.
Published: (2021-07-01)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
by: Dmitry A. Verbenko, et al.
Published: (2021-12-01)

New approved drugs for psoriatic arthritis
by: F.M. Perrotta, et al.
Published: (2016-09-01)

Multiplicity of comorbidities in patients with severe psoriasis
by: N. V. Batkaeva, et al.
Published: (2018-04-01)

Cannot write session to /tmp/vufind_sessions/sess_1m338igvjd0pf195cn04vfkjvs